Development Stage Preclinical
Preclinical
Phase I
Phase II
Phase III
Approved
Preclinical: Animal & In-vitro studies
Thymosin Beta-4
Also known as: TB4, Tβ4
Last updated: 1/22/2026 Last reviewed: 1/22/2026
At a Glance
Thymosin β4 (Tβ4) is a peptide studied for actin-binding and potential roles in tissue repair and regeneration in preclinical settings.
⚠️ Research context: This page summarizes research only and does not provide medical advice or dosing recommendations.
Mechanism of Action (High Level)
Thymosin β4 is well-known for actin binding, with downstream effects described across multiple cell types and model systems.
Evidence Summary
Low Confidence Review ≤3 YearsA review discusses binding modes, biological functions, and clinical applications (with evidence varying by indication). [PMID: 36464872]
Safety & Unknowns (High Level)
- Human efficacy/safety depends on indication and formulation; much of the literature is preclinical.
Regulatory Status
| Region | Status |
|---|---|
| United States (FDA) | Not approved (verify indication-specific context) |
| European Union (EMA) | Not approved (verify indication-specific context) |
| WADA | Check current list (status may change) |
Key Studies
| Year | Type | Topic | Citation |
|---|---|---|---|
| 2023 | Review | Functions and clinical applications overview | [PMID: 36464872] |
📚 See linked items in the Literature section.